Here are the DEF 14A proxy statements from Supernus, Inc. (SUPN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SUPN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SUPN filings page.
Indivior Pharmaceuticals, Inc. is asking shareholders to vote at its 2026 virtual annual meeting on May 13, 2026, on four items: electing eight directors, approving executive pay on an advisory basis, choosing annual say‑on‑pay frequency, and ratifying PwC as auditor.
Management highlights 2025 as a strong transition year. Total net revenue rose 4% to $1.24 billion, driven by SUBLOCADE, whose net revenue grew 13% to a record $856 million. GAAP net income reached $210 million, and adjusted EBITDA increased 20% to $428 million with a 35% margin.
The company completed Phase I of its Indivior Action Agenda, simplified its operating model, and ended 2025 with net leverage of 0.7x. It resolved a legacy DOJ matter and authorized a $400 million share repurchase program, while re‑domiciling from the U.K. to Delaware and aligning governance and compensation with U.S. practices.